Insider · CIK 0001709050
Mark Froimson
Files at PCRX (Pacira BioSciences, Inc.). First filing Mar 19, 2026, latest Mar 19, 2026.
In brief
Mark Froimson files SEC Form 4 as director at PCRX (Pacira BioSciences, Inc.). Since Mar 19, 2026, Mark Froimson has reported 0 open-market buys worth $0 and 1 open-market sell worth $11k, the latest filed on Mar 19, 2026.
A track record needs three past buys with six months of prices behind them; Mark Froimson has 0, so none is measured yet.
The newest scored trade: sold $11k of PCRX on Mar 17, 2026, filed Mar 19, 2026, scored 23 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $11k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PCRX: Pacira BioSciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Pacira BioSciences, Inc. | $11k 500 shares | -2% | +15% from low-19% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 17, 2026 | PCRX Pacira BioSciences, Inc. | 500 0.00% of outstanding | $11k | Mar 17, 2026 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | PCRX Pacira BioSciences, Inc. | AGrant or award Common Stock | +6,405 | $0.00 | $0 | 26,541 | Jun 12, 2026 |
| Jun 10, 2026 | PCRX Pacira BioSciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,891 | $0.00 | $0 | 10,891 | Jun 12, 2026 |
| Mar 17, 2026 | PCRX Pacira BioSciences, Inc. | SOpen-market sale Common Stock | -500 | $21.81 | $11k | 20,136 | Mar 19, 2026 |
| Jun 11, 2025 | PCRX Pacira BioSciences, Inc. | AGrant or award Common Stock | +6,163 | $0.00 | $0 | 20,636 | Jun 13, 2025 |
| Jun 11, 2025 | PCRX Pacira BioSciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +11,279 | $0.00 | $0 | 11,279 | Jun 13, 2025 |
Questions about Mark Froimson
Answered from the filings on this page, as of the latest one.
Is Mark Froimson buying or selling?
In the last 12 months Mark Froimson reported 0 open-market buys worth $0 and 1 open-market sell worth $11k on SEC Form 4; the latest was sold $11k of PCRX on Mar 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Mark Froimson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Froimson has 0.
Where does Mark Froimson file Form 4?
Mark Froimson has filed Form 4 at PCRX (Pacira BioSciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.